These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22030444)

  • 1. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
    Kasichayanula S; Liu X; Zhang W; Pfister M; LaCreta FP; Boulton DW
    Clin Ther; 2011 Nov; 33(11):1798-808. PubMed ID: 22030444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
    Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
    Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
    Macha S; Rose P; Mattheus M; Cinca R; Pinnetti S; Broedl UC; Woerle HJ
    Diabetes Obes Metab; 2014 Feb; 16(2):118-23. PubMed ID: 23859534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
    Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
    Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus.
    Tirucherai GS; LaCreta F; Ismat FA; Tang W; Boulton DW
    Diabetes Obes Metab; 2016 Jul; 18(7):678-84. PubMed ID: 27291448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
    Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
    Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial Comparison of the Pharmacokinetics and Safety of Fixed-dose Combination of Dapagliflozin/Sitagliptin in Western and Korean Healthy Adults.
    Lukka PB; Tang W; Hammarstedt A; Conrad T; Heijer M; Karlsson C; Boulton DW
    Clin Ther; 2024 Sep; 46(9):717-725. PubMed ID: 39179458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P; Pereira MJ; Katsogiannos P; Sjöström CD; Johnsson E; Eriksson JW
    Diabetes Obes Metab; 2017 Sep; 19(9):1276-1288. PubMed ID: 28345814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
    Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
    Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
    Tang W; Engman H; Zhu Y; Dayton B; Boulton DW
    Clin Ther; 2019 Aug; 41(8):1545-1563. PubMed ID: 31266654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
    Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin: a review of its use in patients with type 2 diabetes.
    Plosker GL
    Drugs; 2014 Dec; 74(18):2191-209. PubMed ID: 25389049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
    Zhang W; Krauwinkel WJ; Keirns J; Townsend RW; Lasseter KC; Plumb L; Kadokura T; Ushigome F; Smulders R
    Clin Drug Investig; 2013 Jul; 33(7):489-96. PubMed ID: 23733389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.